Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib Dose-Finding in Acute COPD Exacerbation
NCT03345407Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of nemiralisib in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Nov 2017; status: terminated.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03345407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345407.